AGNM Acron Genomics Inc. featured news, full reports, and detailed charts
Acron Genomics Inc. (AGNM/AGNM.OB) Wrap Up:
Acrongenomics, Inc., a development stage company, focuses on the research and development in the field of life science, including BioLED technology. It has a joint development agreement with Molecular Vision Limited, which developed a technology platform combining microfluidics with an optical detection system based on polymer Light Emitting Diodes (pLED) to deliver point-of-care medical diagnostic devices. The technology platform combining microfluidics and pLED is known as BioLED Technology. The company has exclusive rights to develop and commercialize the BioLED Technology in the medical fields of diabetes management and cardiovascular diseases. It also owns patents for EP-CAM Detection K...www.acrongen.com
2 Employees
Founded in 1999
Acron Genomics Inc. (AGNM:OTC Bulletin Board Market)
LAST $0.17 USD
CHANGE TODAY 0.00 0.00%
VOLUME 0.0
As of November 19, 2009 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Acron Genomics Inc. (AGNM)
|
OPEN
--
|
PREVIOUS CLOSE
$0.17
|
|
|
DAY HIGH
--
|
DAY LOW
--
|
|
|
52 WEEK HIGH
04/15/09 - $0.51
|
52 WEEK LOW
09/18/09 - $0.12
|
|
|
MARKET CAP
4.3M
|
AVERAGE VOLUME 3 mo
5.3K
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
25.4M
|
|
|
AGNM Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
AGNM Top Compensated Officers
Mr. Platon Tzouvalis Msc.
Principal Executive Officer, President, Chief...
Age: 44
Total Annual Compensation: $84.0K
Mr. Ronald Lizée
Chief Financial Officer, Principal Accounting...
Age: 51
Total Annual Compensation: $85.2K
Dr. Manos Topoglidis
Chief Technology Officer, Director and Member...
Age: 36
Total Annual Compensation: $54.0K
Dr. Dimitri Goundis
Consultant
Age: 46
Total Annual Compensation: --
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for Acron Genomics Inc. (AGNM)
Acron Genomics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2009
05/16/2009
Acron Genomics Inc. reported earnings results for the first quarter ended March 31, 2009. For the quarter, the company reported a net loss of $211,282. In contrast, the company posted a net loss of $1.41 million for the same quarter in the previous year.
Acron Genomics Inc. will Change its Ticker to AGNM from AGNME
04/21/2009
Effective April 22, 2009, Acron Genomics Inc. will change its OTCBB stock ticker symbol to AGNM from AGNME.
Acron Genomics Inc. Auditor Raises 'Going Concern' Doubt
04/20/2009
Acron Genomics Inc. filed its 10-K on April 20, 2009 for the period ending December 31, 2008. In this report its auditor, Bdo Dunwoody LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
AGNM Competitors
| Company | Last | Change | |
| No competitor information is available for AGNM. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | AGNM | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
AGNM |
||
AGNM transactions
| Type Date |
Target |
|
Private Placement
September 1, 2009 |
Molecular Vision Ltd. |
More Recent News About Acron Genomics Inc.
Would you like to leave a comment about Acron Genomics Inc. AGNM/AGNM.OB
Find out what social network information about Acron Genomics Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Acron Genomics Inc. there is more great information available at Realpennies.com